



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Vigo, June 26, 2019

In accordance with Article 17 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and Article 226 of the recast Spanish Securities Market Act (*Ley del Mercado de Valores*), the following **RELEVANT EVENT** is hereby reported:

With regard to the regulatory announcements published on 28 January 2019 and 23 May 2019, with submission receipt reference numbers 274,204 and 278,505 respectively, relating to the process of the sale by Pharma Mar, S.A. (“Pharma Mar” or the “Company”) of its subsidiary Zelnova Zeltia, S.A. (“Zelnova”), which includes the sale of the Italian subsidiary Copyr, S.p.A., the Company announces that at the adjourned general meeting of the Company’s shareholders held today in Vigo (Pontevedra), the shareholders authorised the sale of all the shares in Zelnova for a total price of €33,417,000, on the same terms as approved by Pharma Mar’s board on 23 May 2019, to the companies Allentia Invest, S.L. and Safoles, S.A. (together, the “Purchaser”), companies directly and indirectly owned by, among others, Mr Pedro Fernández Puentes, a director of Pharma Mar, and persons connected to him. The shareholders’ authorisation was to comply with Article 230 of the Spanish Companies Act (*Ley de Sociedades de Capital*), with regard to shareholders’ dispensation from the prohibition on directors’ carrying out transactions with the Company, and to the extent applicable Article 160f of the Spanish Companies Act, as regards shareholders’ approval for the sale of assets considered essential.

With this authorisation by the shareholders, the condition to which the transaction was subject is satisfied. Accordingly on 28 June 2019 the sale will be executed with the shares in Zelnova effectively transferred to the Purchaser. Completion of the sale will be reported to the market through a regulatory announcement.